Últimas noticias sobre Simply Good Foods (NASDAQ:SMPL) Bolsa

Simply Good Foods

The Simply Good Foods Co is a consumer packaged food and beverage company. It provides low-carbohydrate, high protein bars, shakes, and other products such as confections, chips, and cookies under the Atkins and Quest brands. The company distributes its products in retail channels, predominantly in North America, including grocery, club, and mass merchandise, as well as through e-commerce, convenience, and other channels. It derives maximum revenue from North America.

Delta Air Lines Jet Overturns At Toronto Pearson Airport Amid Snowstorm — 18 Injured, 3 Critical

Equities

News

Pre-Market Outlook

Markets

Trading Ideas

AEHR

KRUS

SMPL

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: DAL, KRUS, SMPL, AEHR y STZ.

5 acciones en el foco este miércoles: DAL, KRUS, SMPL, AEHR y STZ

The Simply Good Foods Company - Common Stock

The Simply Good Foods Co

FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) will release earnings results for the fourth quarter, after the closing <a href="https://www.benzinga.com/quote/fdx/earnings">bell on Tuesday, June 24.</a>
Analysts expect the Memphis, Tennessee-based company to report quarterly earnings at $5.85 per share, up from $5.41 per share in the year-ago period. FedEx projects to report quarterly revenue at $21.81 billion, compared to $22.1 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 9, FedEx board increased its quarterly dividend from $1.38 to $1.45 per share.
FedEx shares rose 1.2% to close at $226.04 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/fdx/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Barclays analyst Brandon Oglenski maintained an Overweight rating and cut the price target from $350 to $330 on June 3, 2025. This analyst has an accuracy rate of 61%.</li>
<li>UBS analyst Thomas Wadewitz maintained a Buy rating and cut the price target from $331 to $311 on May 28, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Stephens &amp; Co. analyst Daniel Imbro reiterated an Overweight rating with a price target of $300 on May 20, 2025. This analyst has an accuracy rate of 67%.</li>
<li>BMO Capital analyst Fadi Chamoun maintained a Market Perform rating and cut the price target from $275 to $260 on May 19, 2025. This analyst has an accuracy rate of 76%.</li>
<li>B of A Securities analyst Ken Hoexter maintained a Buy rating and cut the price target from $272 to $270 on May 13, 2025. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying FDX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/FDX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23025629/image-322-1024x557.png" alt="" class="wp-image-957574" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23025629/image-322-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23025629/image-322-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23025629/image-322-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23025629/image-322.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Analyst Ratings

FedEx Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Monday.
Following the market opening Monday, the Dow traded up 0.50% to 42,417.90 while the NASDAQ gained 0.61% to 19,566.92. The S&amp;P 500 also rose, gaining, 0.62% to 6,004.66.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.7% on Monday.
In trading on Friday, energy stocks fell by 0.1%.
Top Headline
Shares of FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) gained around 5% on Monday after the company posted results for the third quarter.
The company reported quarterly sales of $585.52 million, surpassing analyst expectations of $580.50 million and representing a 5.9% year-over-year gain.
The company reported quarterly adjusted earnings per share of $4.27, missing the street view of $4.29.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) shares shot up 306% to $1.5001. Dr Ashleys Limited and Impact BioMedical Inc. announced a strategic merger.</li>
<li>Shares of Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) got a boost, surging 139% to $0.6464 after tumbling 18% on Friday.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares were also up, gaining 91% to $40.08 after the company announced positive topline results from its Phase 2b NAVIGATE trial evaluating CD388, a non-vaccine preventative of seasonal influenza.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) shares dropped 50% to $2.6741.</li>
<li>Shares of Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) were down 32% to $1.13. Lipella Pharmaceuticals announced delisting from Nasdaq Capital Market.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) was down, falling 47% to $2.44. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $72.94 while gold traded up 0.3% at $3,397.20.
Silver traded up 0.6% to $36.235 on Monday, while copper rose 0.3% to $4.8495.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.3%, while Spain's IBEX 35 Index rose 0.2%. London's FTSE 100 slipped 0.2%, Germany's DAX 40 declined 0.2% and France's CAC 40 fell 0.6% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.13%, Hong Kong's Hang Seng Index gaining 0.67%, China's Shanghai Composite rising 0.65% and India's BSE Sensex falling 0.62%.
Economics
<ul class="wp-block-list">
<li>The S&amp;P Global US services PMI fell to 53.1 in June versus 53.7 in the previous month, and compared to market expectations of 52.9.</li>
<li>The S&amp;P Global US manufacturing PMI came in unchanged from the previous month at 52 in June.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46051985/amd-to-rally-more-than-36-here-are-10-top-analyst-forecasts-for-monday">AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

Intraday Update

CDTX

CMPS

INDP

LIPO

SANW

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results

Kroger Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) first-quarter results reflected that the company "continues to execute well, leveraging its fresh and own brands assortments, robust loyalty program, and enhanced digital capabilities," according to Telsey Advisory Group.
The Kroger Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e301e08430dee0001c88c8d/joseph-feldman">Analyst Joseph Feldman</a> reiterated an Outperform rating and raised the price target from $73 to $82.
The Kroger Thesis: The company reported adjusted earnings of $1.49 per share, beating the consensus of $1.45 per share, with higher-than-expected same-store sales, despite "an uneven consumer spending environment," Feldman said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Kroger raised its same-store sales, ex-fuel, guidance for 2025 from 2%-3% to 2.25%-3.25% and "conservatively maintained its profit projections," he added.
"Kroger is operating from a position of strength, with momentum in the business and a solid strategy for 2025+," the analyst wrote.
Feldman expects Kroger's growth and market share gains to continue, driven by the company&#8217;s expansion into new geographies, increasing its product assortment, improving its digital experience, and building loyalty with personalization and paid memberships.
KR Price Action: At the time of publication on Monday, Kroger&#8217;s shares had risen by 2.77% to $73.96.
Read More: <a href="https://www.benzinga.com/insights/analyst-ratings/25/06/45946624/canaan-stock-a-deep-dive-into-analyst-perspectives-8-ratings">&nbsp;Vegas Grocery Prices Rise 2%, Walmart Remains Cheapest: Analyst</a>
Photo: Shutterstock

Analyst Color

Reiteration

Kroger Posts Q1 Beat: Analyst Raises Price Target To Reflect Continued Growth, Market Share Gains

WIIM

Li Auto shares are trading higher after the company reportedly filed for its Li i6 SUV model, with a launch expected in September.

Morgan Stanley analyst Ryan Kenny maintains Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Overweight and raises the price target from $159 to $192.

Morgan Stanley Maintains Overweight on Houlihan Lokey, Raises Price Target to $192

Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) has outperformed the market over the past 5 years by 9.95% on an annualized basis producing an average annual return of 24.72%. Currently, Popular has a market capitalization of $7.16 billion. 
Buying $100 In BPOP: If an investor had bought $100 of BPOP stock 5 years ago, it would be worth $288.93 today based on a price of $104.50 for BPOP at the time of writing.
<h3>Popular's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750689919_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPOP

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Tensions in <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46050890/bitcoin-ethereum-xrp-dogecoin-weaken-on-iran-israel-tensions-reclaim-105000-or-brace-for-sideways-summer">the Middle East</a> have caused the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to go down by under $100,000 in the last several days. A Benzinga reader poll may have predicted that move and could show what happens next.
What Happened: The leading cryptocurrency, Bitcoin, continues to see increased interest and adoption from investors thanks to its maximum supply, institutional buying, and other elements.
Bitcoin hit new all-time highs in November around the 2024 presidential election and jumped to new highs several times in 2025.
A Benzinga poll recently asked if a new all-time high was likely in the short term.
"Bitcoin trades near $107,500 today. Which of the following do you think happens next?" Benzinga asked.
The results were:
<ul class="wp-block-list">
<li>Bitcoin hits new all-time highs (over $112,000): 50%</li>
<li>Bitcoin trades below $100,000: 50%</li>
</ul>
Readers were split in the poll on which level would be hit first. Since the poll was conducted, Bitcoin briefly dipped under the $100,000 level. Over the last 24 hours, it has traded between $98,286.21 and $102,136.32.
The drop under $100,000 could prove to be short-lived, and Bitcoin could hit new all-time highs, as predicted by the other 50% of readers in the poll.
Bitcoin hit a high of $111,970.17 in May 2025, which was also the last month that Bitcoin traded under $100,000.
While Bitcoin could remain volatile and stuck in the range under all-time highs, easing of Middle East tensions with no retaliations by Iran could see markets climb higher, including cryptocurrency prices.
Read Also:<a href="https://www.benzinga.com/25/05/45594252/exclusive-no-hodling-for-congress-48-say-elected-members-shouldnt-be-able-to-buy"> EXCLUSIVE: No HODLing For Congress, 48% Say Elected Members Shouldn&#8217;t Be Able To Buy Cryptocurrency</a>
What's Next: Bitcoin leads the cryptocurrency market by price and volume and continues to experience strong demand from both retail and institutional investors.
Another <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45871245/exclusive-bitcoin-to-hit-200k-in-2025-15-say-yes-while-many-see-new-all-time-highs-coming">recent Benzinga poll </a>asked readers to predict the highest price Bitcoin will hit before the end of the year.
"Bitcoin hit new all-time highs of nearly $112,000 in May 2025. Do you believe this will be the top price for BTC in 2025 or will the leading cryptocurrency hit new highs later this year?&#8221; Benzinga asked.
The results were:
<ul class="wp-block-list">
<li>Bitcoin will hit $112K to $130K: 32%</li>
<li>Bitcoin will hit $130K to $150K: 24%</li>
<li>Bitcoin will hit $150K to $200K: 15%</li>
<li>Bitcoin will hit $200K+: 15%</li>
<li>Bitcoin has already topped at $112K: 14%</li>
</ul>
The poll found that readers are optimistic about Bitcoin&#8217;s future, with 86% predicting it will reach new all-time highs later this year.
In the poll, the most popular options were the $112,000 to $130,000 range and the $130,000 to $150,000 range at 32% and 24% respectively.
Over half of the respondents see Bitcoin reaching $112,000 to $150,000 before the end of the year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45932660/exclusive-sp-500-new-all-time-highs-again-2025">EXCLUSIVE: S&amp;P 500 To Hit New All-Time Highs Again In 2025? Majority Say Yes, 27% Predict This Range</a></li>
</ul>
The study was conducted by Benzinga from June 16, 2025, through June 21, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 137 adults.
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$BTC

Will Bitcoin Hit New All-Time Highs After Dip Under $100K? Here's What New Poll Predicts

<a href="https://www.axios.com/2025/06/23/whatsapp-house-congress-staffers-messaging-app">https://www.axios.com/2025/06/23/whatsapp-house-congress-staffers-messaging-app</a>

General

'WhatsApp banned on House staffers' devices'- Axios

Morgan Stanley analyst Ryan Kenny upgrades Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) from Underweight to Overweight and raises the price target from $42 to $68.

Upgrades

Morgan Stanley Upgrades Moelis to Overweight, Raises Price Target to $68

Last week's fundamental news largely followed the consensus expectations. Most eyes were on the Federal Reserve, which <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46006680/powell-holds-line-on-interest-rates-blames-tariff-uncertainty-for-delay-in-cuts">held the interest rate at 4.5%</a> despite President Donald Trump's pleas for an interest rate cut. In fact, Trump has called for the rate to be lowered as much as 2.5%, which would bring it to 2%.
Still, Fed Chairman Jerome Powell is mindful of the Trump administration's tariff policy and its influence on inflation, despite two more anticipated rate cuts in 2025.
&#8220;No one holds these &#8230; rate paths with a great deal of conviction, and everyone would agree that they&#8217;re all going to be data dependent,&#8221; Powell <a href="https://www.reuters.com/business/feds-powell-says-he-expects-see-more-tariff-driven-price-hikes-coming-months-2025-06-18/">said</a> at the press conference.
Other notable central bank actions were the Bank of Japan's hold at 0.5%, a widely anticipated Swiss National Bank's cut to 0%, and the Bank of England's hold at 4.25%.
The most <a href="https://singaporeforexclub.com/geopolitics-and-forex">important geopolitical event</a> of the week was the US involvement in the Israel-Iran conflict, which included airstrikes on three nuclear facilities. These actions could disrupt the global oil supply and drive oil prices higher, strengthening the Canadian dollar.
The week ahead will bring news from European manufacturing and speeches from central bank leaders, including Powell and his UK counterpart, Andrew Bailey.
<h2 class="wp-block-heading">Key News:</h2>
<ul class="wp-block-list">
<li>Monday:  EUR, GBP, and USD – Manufacturing/Services PMI</li>
<li>Tuesday: CAD – CPI, USD – Powell Testify, GBP – Bailey Speech</li>
<li>Wednesday: AUD – CPI, USD – Powell Testifies</li>
<li>Thursday: GBP-  Bailey Speech, USD – GDP, Unemployment Claims</li>
<li>Friday: CAD – GDP, USD – Core PCE Price Index</li>
</ul>
<h2 class="wp-block-heading">Pairs In Focus</h2>
<h3 class="wp-block-heading">1. AUD CAD</h3>
This pair has been in focus for two consecutive weeks. After a first breakout, it staged a pullback but failed to reach the resistance at 0.89450, and closed the week below the key level of 0.88800.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="537" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131353/AUDCAD_2025-06-22_16-54-41-1024x537.png" alt="" class="wp-image-14768" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131353/AUDCAD_2025-06-22_16-54-41-1024x537.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131353/AUDCAD_2025-06-22_16-54-41-300x157.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131353/AUDCAD_2025-06-22_16-54-41-768x403.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131353/AUDCAD_2025-06-22_16-54-41.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
AUD/CAD daily chart, Source: TradingView
The ongoing conflict with Iran, which is pushing the price of oil higher, could be the trigger that solidifies the lower low on this pair, as the Canadian dollar benefits from higher oil prices.
<h3 class="wp-block-heading">2. GBP AUD</h3>
The pound has benefited from the rate decision being held, despite three dissents instead of the anticipated two. After a brief pullback, which failed to reach the support at 2.05, the price rebounded. However, to turn bullish, it should clearly close above 2.0845 on the daily chart.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="542" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131404/GBPAUD_2025-06-22_16-54-51-1024x542.png" alt="" class="wp-image-14769" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131404/GBPAUD_2025-06-22_16-54-51-1024x542.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131404/GBPAUD_2025-06-22_16-54-51-300x159.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131404/GBPAUD_2025-06-22_16-54-51-768x406.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23131404/GBPAUD_2025-06-22_16-54-51.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
GBP/AUD daily chart, Source: TradingView
If that occurs, further rallies are possible toward the 2.10400 resistance level, and possibly higher.
<h3 class="wp-block-heading">Notes:</h3>
<ul class="wp-block-list">
<li>AUD NZD: Briefly broke out of the range higher before retracing. The short-term bias remains bullish.</li>
<li>AUD CHF: Tried to challenge the key level at 0.53240 and failed multiple times. The trend remains bearish.</li>
<li>AUD SGD: After four attempts to stay above the 0.83450 level, it turned bearish and will likely test support at 0.82650.</li>
<li>AUD JPY:  Price action is tightening, indicating that a breakout might be on the cards soon. Short-term potential is higher to the upside.</li>
<li>CHF JPY:  Continues the strong bullish momentum, with a potential to move about 150 pips more and reach the key level and a previous high at 180.</li>
<li>CAD JPY: Remains in a relatively tight consolidation, but the bias is to the upside.</li>
<li>EUR AUD: After a brief pullback, the price continues reaching for highs from March.</li>
<li>EUR/JPY: Reached a new yearly high. Temporary resistance above could be around 169.270.</li>
<li>EUR NZD: Rallied and made a fresh high. A temporary resistance could be around 1.94880.</li>
<li>GBP JPY: Overcame strong resistance around 196.400. The key levels above are around 198.200 and 199.800.</li>
<li>NZD JPY: Made a marginally higher high before declining late in the week. The bias is slightly bullish.</li>
<li>NZD CHF: Strongly rejected from the 0.49265 key level. A continuation of the bearish trend could test the support at 0.48.</li>
</ul>
Disclaimer: Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. Singapore Forex Club is not responsible for any financial decisions based on this article's contents. We provide research and promote <a href="https://singaporeforexclub.com/how-to-start-trading-forex-in-singapore" target="_blank" rel="noreferrer noopener">forex trading in Singapore</a>, and readers may use this data for information and educational purposes only.

Forex

Opinion

Middle East Conflict Could Help The Canadian Dollar

Guggenheim analyst Ronald Jewsikow reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and maintains $175 price target.

TSLA

Guggenheim Reiterates Sell on Tesla, Maintains $175 Price Target

Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are on watch Monday morning as escalating geopolitical tensions in the Middle East are raising fears of oil supply disruptions.
What To Know: This follows the U.S. State Department's worldwide <a href="https://www.benzinga.com/news/travel/25/06/46045416/us-issues-worldwide-caution-after-strikes-on-irans-nuclear-sites-state-department-warns-of-airspace-closures-travel-chaos-and-rising-threats-to-americans-abroad">security alert</a> after American airstrikes on Iranian nuclear sites and Iran's subsequent threats against U.S. interests.
Markets reacted to the possibility of <a href="https://www.benzinga.com/news/politics/25/06/46047021/iran-threatens-strait-of-hormuz-after-us-bombs-its-nuclear-sites-shipping-traffic-plunges">supply shocks</a> after Iran's parliament authorized potential closure of the Strait of Hormuz, a strategic chokepoint through which nearly 20% of the world's petroleum passes. While the vote was symbolic, it underscored the region's volatility and heightened the risk premium on crude.
Exxon Mobil, one of the world's largest publicly traded oil and gas companies, stands to benefit from rising oil prices in the face of constrained global supply.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46050799/hims-hers-health-stock-is-tumbling-monday-whats-happening">Hims &amp; Hers Health Stock Is Tumbling Monday: What&#8217;s Happening?</a>
As a vertically integrated energy giant with upstream and downstream operations, XOM's profitability is closely tied to crude oil prices, which are sensitive to geopolitical instability in major production and transport regions like the Middle East.
With Iranian airspace closures, restricted travel and increasing regional conflict, investors are likely rotating into energy stocks Monday as a hedge, lifting shares of oil majors like Exxon Mobil. 
The firm's global scale and upstream exposure could position it well amid rising energy demand and tightening supply concerns.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XOM has a 52-week high of $126.34 and a 52-week low of $97.80.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46050843/indonesia-energy-indo-stock-soars-amid-middle-east-tensions-oil-disruption-fears">Indonesia Energy (INDO) Stock Soars Amid Middle East Tensions, Oil Disruption Fears</a>
<h2 class="wp-block-heading">How To Buy XOM Stock</h2>
By now you're likely curious about how to participate in the market for Exxon Mobil &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Exxon Mobil, which is trading at $114.52 as of publishing time, $100 would buy you 0.87 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

Exxon Mobil (XOM) Stock On Watch Amid Middle East Tensions: What's Going On?

Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), a go-to supplier for chip giants like Taiwan Semiconductor Manufacturing Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and Samsung Electronics Co (OTCPK:SSNLF), just flashed a golden signal on its chart &#8211; a <a href="https://www.benzinga.com/topic/golden-cross">technical Golden Cross</a> &#8211; as the stock surged nearly 25% year to date.
For the uninitiated, a Golden Cross occurs when a stock's short-term moving average breaks above its long-term average, hinting at sustained bullish momentum. 
And Lam just did it in style &#8211; its 50-day simple moving average (SMA) has now decisively crossed above its 200-day average, turning heads in the semiconductor corner of Wall Street.
Read Also: <a href="https://www.benzinga.com/insights/news/25/06/45976861/heres-how-much-you-would-have-made-owning-lam-research-stock-in-the-last-10-years">Here&#8217;s How Much You Would Have Made Owning Lam Research Stock In The Last 10 Years</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623"><img loading="lazy" decoding="async" width="627" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23090737/Screenshot-2025-06-23-at-5.06.17-PM.png" alt="" class="wp-image-958119" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23090737/Screenshot-2025-06-23-at-5.06.17-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23090737/Screenshot-2025-06-23-at-5.06.17-PM-300x233.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">From Fab Floors to Stock Floors</h2>
Lam isn't just another tech stock &#8211; it's a critical cog in the global chip machine, making the tools that power deposition and etch processes. That's tech-speak for helping build and carve microscopic chip features layer by layer. With a dominant share in etch and a solid second place in deposition, Lam's gear sits inside the fabs of TSMC, Samsung, Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>).
Despite a 12% dip over the past month, LRCX is now showing signs of strength. With its price at $90.49, above the 50-day SMA of $79.38 and the 200-day SMA of $77.42, multiple technical signals are flashing green. The MACD (moving average convergence/divergence) at 3.33 and RSI (relative strength index) at 62.01 further support a growing bullish trend.
<h2 class="wp-block-heading">Betting On The Memory Cycle?</h2>
Lam's reliance on memory chipmakers (DRAM and NAND) has made it more cyclical than some peers &#8211; but that's turning into a feature, not a bug. 
As demand rebounds and capex from big players like Samsung and Micron ramps back up, Lam could ride the wave of equipment upgrades and restocking.
<h2 class="wp-block-heading">The Quiet Golden Opportunity</h2>
The Golden Cross may be quiet, but it&#8217;s loud enough for traders and long-term investors to pay attention. With AI, advanced packaging, and chip expansion cycles ramping globally, Lam Research may have just etched a path higher.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46034864/this-could-be-amds-biggest-ai-win-mi400-chips-may-power-stargate">This Could Be AMD&#8217;s Biggest AI Win: MI400 Chips May Power Stargate</a></li>
</ul>
Photo: Shutterstock

Technicals

Signals

Tech

INTC

LRCX

SSNLF

This TSMC, Samsung Supplier Just Made A Golden Cross

Correction :UBS analyst Joseph Spak maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and raises the price target from $190 to $215. ( Rating Changed)

Correction :UBS Maintains Sell on Tesla, Raises Price Target to $215

Morgan Stanley analyst Ryan Kenny upgrades Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) from Equal-Weight to Overweight and raises the price target from $175 to $312.

Morgan Stanley Upgrades Evercore to Overweight, Raises Price Target to $312

Guggenheim analyst Jonathan Lee maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Buy and lowers the price target from $360 to $335.

Guggenheim Maintains Buy on Accenture, Lowers Price Target to $335

On Sunday, Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46044198/exelixis-announces-zanzalintinib-in-combination-with-an-immune-checkpoint-inhibitor-improved-overa" rel="noreferrer noopener">combined with atezolizumab</a>.
The study includes patients with previously treated non-microsatellite instability (MSI)-high <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">metastatic colorectal cancer (CRC)</a>.
Zanzalintinib in combination with Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) atezolizumab (Tecentriq) demonstrated a statistically significant improvement in overall survival (OS) versus Bayer AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>) Stivarga (regorafenib).
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45418036/exelixis-stock-soars-as-analysts-applaud-raised-2025-guidance-q1-earnings-beat" target="_blank" rel="noreferrer noopener">Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat</a>
These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial.
The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM).
The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified.
Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference.
Following this positive news, analysts at William Blair said that the announcement &#8220;represents the first pivotal success from the zanzalintinib program, and we are encouraged that the STELLAR-303 study met one of the dual primary endpoints of overall survival among the intent-to-treat population, representing the largest commercial opportunity (risk-adjusted U.S. peak sales of $875 million, according to our estimates).&#8221;
Management had earlier projected that zanzalintinib could reach $5 billion in U.S. net product sales by 2033, with 45% expected from genitourinary cancers, another 45% from gastrointestinal cancers, and the remaining 10% from head-and-neck cancers. Analyst Andy Hsieh asserted that the early positive results from the STELLAR-303 trial mark the first step toward reaching that target.
He added, &#8220;From a stock perspective, given its substantial and likely durable cash flow generation into early 2030, we continue to believe Exelixis provides investors with a highly defensive investment profile. We also believe that the strategic positioning outlined by Exelixis should drive moderate growth into the next decade.&#8221;
Adding to Exelixis&#8217; recent positive developments, its partner Ipsen also recently achieved a regulatory milestone.
On Friday, Exelixis&#8217; partner Ipsen received a positive opinion from the European Medicine Agency&#8217;s Committee for Medicinal Products for Human Use for Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic and pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46022267/exelixis-partner-ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-patients-with" rel="noreferrer noopener">other than somatostatin analogs</a>.
A regulatory decision by the European Medicines Agency is anticipated in 2025. In March 2025, the U.S. Food and Drug Administration approved <a href="https://www.benzinga.com/pressreleases/25/06/b46022267/exelixis-partner-ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-patients-with" target="_blank" rel="noreferrer noopener">Cabometyx in this setting</a>.
Price Action: EXEL stock is trading higher by 11.1% to $44.85 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/05/45703024/pfizer-reports-survival-gains-in-colorectal-cancer-study-combo-therapy-cuts-death-risk-by-over-50" target="_blank" rel="noreferrer noopener">Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

BAYRY

EXEL

RHHBY

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/06/2025-06-23_09h24_49.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Momo Crowd Buys Shallow Dip</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-dip-buying-bitcoin-selling-spy-mc-06232025">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul class="wp-block-list">
<li>The chart shows the stock market reaction to the U.S. bombing Iran is muted.</li>
<li>RSI on the chart shows the stock market is neither overbought nor oversold and can go in either direction.</li>
<li>On Sunday evening when stock futures opened, they opened lower about 1%.&nbsp; The momo crowd immediately bounced to buy the shallow dip.&nbsp; The momo crowd has continued to buy stocks as of this writing.</li>
<li>There is no smart money buying as of this writing in the premarket.&nbsp; Presumably, the reason is smart money wants to know how Iran will respond.&nbsp; In contrast, the momo crowd has already concluded that Iran is a paper tiger.</li>
<li>Iran has many options.  It will be total arrogance for anyone to believe they know how Iran is going to react.  Prudent investors should start from our Second Law of Investing and Trading, which states "Nobody knows with certainty what is going to happen next in the markets," and our Third Law, which states "Making investing and trading decision based on probabilities is the only realistic and profitable approach."</li>
<li>The highest probability scenario continues to be what we shared with you on June 17:</li>
</ul>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">This morning, at a time when selling is taking place in stocks on heightened concern about the Israel Iran war, in our analysis, the highest probability scenario is Iran capitulation on its ambitions to build a nuclear weapon.  If this highest probability scenario comes true, investors should look ahead to the following:
</blockquote>
<ul class="wp-block-list">
<li>&#8220;Israeli stocks will go up.&nbsp; There is a new buy signal on Israel ETF EIS in ZYX Allocation.</li>
<li>Defense stocks will go down.</li>
<li>Oil stocks will go down</li>
<li>Oil will go down.</li>
<li>Such a development will be negative for gold but expect central banks to buy the dip.</li>
<li>Such a development will be negative for silver.  Our likely call will be to start a trade around position in silver.</li>
<li>Such a development will be negative for the Chinese stock market.</li>
<li>Such a development will be negative for Russia.</li>
<li>Such a development will be negative for U.S. Treasuries.&nbsp;</li>
<li>Such a development will be positive for the Taiwanese stock market.</li>
<li>Such a development will be positive for the U.S. stock market.</li>
<li>Such a development will be positive for the Indian stock market.</li>
<li>Such a development will be positive for European stock markets.</li>
<li>Such a development will be positive for the U.S. dollar.&#8221;</li>
<li>There is no value to be added by regurgitating everything that is in mainstream media. Prudent investors should pay attention to a statement coming from Russia that the media has ignored.  Deputy Chairman of the Security Council of Russia Dmitry Medvedev said, "A number of countries are ready to directly supply Iran with their own nuclear warheads."   In our analysis, the only four countries that are even plausible are Russia, North Korea, China, and Pakistan.  </li>
<li>Prudent investors should also pay attention to the fact that it appears 400kg of Iran's enriched uranium is missing.&nbsp; This is enough to make ten nuclear bombs.&nbsp; It is likely that Iran moved this uranium to a secure secret location before the attacks.&nbsp;&nbsp;</li>
<li>Investors should think in different time frames.&nbsp; Even if Iran does not respond vigorously, in the short term, Iran may secretly build a nuclear weapon over the next year, unless there is a regime change.&nbsp;&nbsp;</li>
<li>Prudent investors should also note that Iran's parliament has passed a resolution calling for the blockage of the Strait of Hormuz.&nbsp; About 25% of the world's oil is transported through the Strait of Hormuz.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Meta Platforms Inc (META), and Tesla Inc (TSLA).
In the early trade, money flows are neutral in Microsoft Corp (MSFT)and Alphabet Inc Class C (GOOG).
In the early trade, money flows are negative in NVIDIA Corp (NVDA).
In the early trade, money flows are positive in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is seeing selling on Iran risk.  The price action in bitcoin goes against the narrative of bitcoin promoters that bitcoin is a hedge against geopolitics.
<h4 class="wp-block-heading">Arora Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Government

Long Ideas

Market Summary

Politics

Momo Crowd Buys Stocks Believing Iran Is A Paper Tiger, Russia Talks Nuclear Warheads For Iran

Guggenheim analyst John Heinbockel maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Buy and raises the price target from $73 to $78.

Guggenheim Maintains Buy on Kroger, Raises Price Target to $78

<a href="https://www.bloomberg.com/news/articles/2025-06-23/india-us-eye-trade-deal-by-july-though-challenges-remain?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-23/india-us-eye-trade-deal-by-july-though-challenges-remain?embedded-checkout=true</a>

Comments

Simply Good Foods

Noticias

Últimas noticias sobre Simply Good Foods (NASDAQ:SMPL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL